Up-Regulation of PARP1 Expression Significantly Correlated with Poor Survival in Mucosal Melanomas.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
05 05 2020
Historique:
received: 15 04 2020
revised: 29 04 2020
accepted: 02 05 2020
entrez: 9 5 2020
pubmed: 10 5 2020
medline: 24 2 2021
Statut: epublish

Résumé

Mucosal melanoma is rare and associated with poorer prognosis in comparison to conventional melanoma subtypes. Little is known about the prognostic significance as well as possible associations between PARP1 and immunologic response in mucosal melanoma. PARP1, PD-L1 and IDO1 immunostains were performed on 192 mucosal melanomas including 86 vulvar, 89 sinonasal, and 17 anorectal melanomas. By Kaplan-Meier analyses, high PARP1 expression correlated with worse overall and melanoma-specific survival (log-rank Increased expression of PARP1 is an independent negative prognostic marker in mucosal melanomas. The association between PARP1 and IDO1 and their combined adverse prognostic role raise the potential of combined therapy in mucosal melanoma.

Identifiants

pubmed: 32380691
pii: cells9051135
doi: 10.3390/cells9051135
pmc: PMC7290913
pii:
doi:

Substances chimiques

B7-H1 Antigen 0
CD274 protein, human 0
IDO1 protein, human 0
Indoleamine-Pyrrole 2,3,-Dioxygenase 0
PARP1 protein, human EC 2.4.2.30
Poly (ADP-Ribose) Polymerase-1 EC 2.4.2.30

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

J Immunol. 2006 Oct 15;177(8):5639-46
pubmed: 17015752
Trends Immunol. 2013 Mar;34(3):137-43
pubmed: 23103127
Mol Oncol. 2019 Jul;13(7):1577-1588
pubmed: 31131495
J Biol Chem. 2012 Apr 13;287(16):12975-84
pubmed: 22337872
Eur J Cancer. 2017 May;76:167-182
pubmed: 28324751
Hepatology. 2010 Jan;51(1):255-66
pubmed: 20034026
Cancer. 1998 Oct 15;83(8):1664-78
pubmed: 9781962
Mol Clin Oncol. 2019 Aug;11(2):116-126
pubmed: 31281645
Nat Med. 2003 Oct;9(10):1269-74
pubmed: 14502282
Int J Cancer. 2014 Jun 15;134(12):2961-71
pubmed: 24272143
Curr Mol Biol Rep. 2016 Mar;2(1):10-16
pubmed: 27042400
DNA Repair (Amst). 2011 Oct 10;10(10):1003-13
pubmed: 21840268
J Biol Chem. 2015 Nov 27;290(48):28675-82
pubmed: 26429911
Eur J Cancer. 2017 Aug;81:36-44
pubmed: 28600969
J Hematol Oncol. 2019 Sep 14;12(1):98
pubmed: 31521196
Curr Opin Struct Biol. 2018 Dec;53:187-198
pubmed: 30481609
Curr Med Chem. 2011;18(15):2240-6
pubmed: 21517755
BMC Cancer. 2013 Nov 05;13:523
pubmed: 24191908
Clin Cancer Res. 2017 Jul 15;23(14):3711-3720
pubmed: 28167507
Nucleic Acids Res. 2014 Jun;42(11):7028-38
pubmed: 24861619
Cancers (Basel). 2020 Feb 08;12(2):
pubmed: 32046278
Cells. 2019 Dec 22;9(1):
pubmed: 31877876
Oncotarget. 2014 May 15;5(9):2778-91
pubmed: 24784564
Oncogene. 2017 Aug 17;36(33):4682-4691
pubmed: 28394338
Cancer Manag Res. 2018 Dec 14;10:6985-6996
pubmed: 30588103
Sci Rep. 2019 Feb 12;9(1):1853
pubmed: 30755715
Clin Cancer Res. 2011 Nov 15;17(22):6985-91
pubmed: 22068654
Hum Pathol. 2005 Jul;36(7):724-31
pubmed: 16084940
Biochem Pharmacol. 2019 Sep;167:33-43
pubmed: 30910692
Cancer Immunol Res. 2019 Jan;7(1):136-149
pubmed: 30401677
PLoS One. 2013 Jun 06;8(6):e66008
pubmed: 23762456
Nature. 2019 Aug;572(7768):254-259
pubmed: 31316209
Immunology. 2013 Aug;139(4):428-37
pubmed: 23489378
Ann N Y Acad Sci. 2009 Aug;1171:32-7
pubmed: 19723035
EMBO J. 2019 Oct 4;38(21):e103479
pubmed: 31633196
J Oncol. 2018 Dec 2;2018:1908065
pubmed: 30631354
J Exp Med. 1999 May 3;189(9):1363-72
pubmed: 10224276
Trends Pharmacol Sci. 2018 Mar;39(3):307-325
pubmed: 29254698
Curr Top Med Chem. 2014;14(20):2346-65
pubmed: 25434352
EBioMedicine. 2018 Dec;38:47-56
pubmed: 30472087
Expert Opin Ther Targets. 2007 May;11(5):695-705
pubmed: 17465726

Auteurs

Piotr Donizy (P)

Department of Pathomorphology and Oncological Cytology, Wroclaw Medical University, 50-556 Wroclaw, Poland.

Cheng-Lin Wu (CL)

Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70403, Taiwan.

Jason Mull (J)

Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

Masakazu Fujimoto (M)

Department of Pathology, Wakayama Medical University, Wakayama 641-8510, Japan.

Agata Chłopik (A)

Department of Pathology, Poznan University Medical Sciences and Greater Poland Cancer Center, 61-701 Poznan, Poland.

Yan Peng (Y)

Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

Sara C Shalin (SC)

Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

M Angelica Selim (MA)

Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA.

Susana Puig (S)

Melanoma Unit, Department of Dermatology, Hospital Clínic de Barcelona, IDIBAPS, Centre of Biomedical Research on Rare Diseases (CIBERER), ISCIII, 08036 Barcelona, Spain.

Maria-Teresa Fernandez-Figueras (MT)

Department of Pathology, Hospital Universitari Germans Trias i Pujol, Hospital Universitari General de Catalunya, Grupo QuironSalud, Universitat Internacional de Catalunya, 08916 Barcelona, Spain.

Christopher R Shea (CR)

Department of Medicine, Section of Dermatology University of Chicago, Chicago, IL 60637, USA.

Wojciech Biernat (W)

Department of Pathology, Medical University of Gdansk, 80-210 Gdansk, Poland.

Janusz Ryś (J)

Department of Tumor Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, 31-115 Krakow Branch, Poland.

Andrzej Marszalek (A)

Department of Pathology, Poznan University Medical Sciences and Greater Poland Cancer Center, 61-701 Poznan, Poland.

Mai P Hoang (MP)

Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH